Patent · US Active

(4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate

US11147814B2 · kind B2 · utility

3Cited by

36References

20Claims

0Family size

Assignee

Centrexion Therapeutics Corporation · US

Inventors

Markus Ostermeier · Biberach an der Riß, DE
Ulrike Werthmann · Biberach an der Riß, DE

Key dates

Filing date	Feb 11, 2020
Grant date	Oct 19, 2021
Priority date	—
Expiry date	Feb 11, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D405/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.